Treatment Patterns and Associated Clinical Outcomes in Type 2 Diabetes Patients Initiating Second-Line Glucose-Lowering Therapy: Interim Analysis of Baseline Data from Turkey Arm of the Global DISCOVER Study

Basit Öğe Kaydı
dc.contributor.authorBayram, Fahri
dc.contributor.authorSari, Ramazan
dc.contributor.authorKucukler, Ferit Kerim
dc.contributor.authorAraz, Mustafa
dc.contributor.authorColak, Ramis
dc.contributor.authorBaspinar, Osman
dc.contributor.authorTetiker, Tamer
dc.date.accessioned2021-11-01T15:06:14Z
dc.date.available2021-11-01T15:06:14Z
dc.date.issued2021
dc.department[Belirlenecek]
dc.description.abstractObjective: To evaluate the treatment patterns and associated clinical outcomes in Type 2 diabetes (T2D) patients initiating a second-line glucose-lowering therapy. Material and Methods: This paper presents a preliminary subgroup analysis of the baseline data collected from 536 patients [mean (standard deviation) age: 55.1 (10.0) years, 50.2% were males] in the Turkey arm of global observational DISCOVER study among T2D patients initiating second-line glucose-lowering therapy. Patient demographics, disease (duration, complications) and treatment (type of regimens, modifications) characteristics, hemoglobin A1c (HbA1c), low-density lipoprotein-cholesterol (LDL-C), and systolic blood pressure (BP) target achievement rates and the patient-reported outcomes were recorded at the initiation of second-line therapy. Results: Overall, 11.7% of patients were HbA1c target of <7% at baseline, 62.5% were systolic BP target of <140 mmHg and 21.2% were LDL-C target of <100 mg/dL. Major and minor hypoglycemic events were noted in 5.5% and 10.7% of patients, while macro and microvascular complications in 17.2% and 20.1% of patients, respectively. Metformin monot- herapy (47.9%) and metformin+sulfonylurea combination (22.6%) were the two most common first-line therapies. However, insulin (32.3%) was the most commonly prescribed second-line agent. Lifestyle assessment revealed a healthy lifestyle in 50.7% of patients. Conclusion: Our finding revealed a failure to achieve HbA1c, LDL-C, and systolic BP targets and a high rate of diabetes-related complications before initiation of second-line therapy in a significant proportion of Turkish T20 patients. Thus, emphasizing a need for more aggressive risk factor screening and modification at early disease stages and earlier treatment intensification among T2D patients.
dc.description.sponsorship[D1690R00002]en_US
dc.description.sponsorshipThe study is funded by AstraZeneca Turkey.The study is funded by AstraZeneca Project code: D1690R00002en_US
dc.identifier.doi10.25179/tjem.2021-81148
dc.identifier.endpage215en_US
dc.identifier.issn1301-2193
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85110868115
dc.identifier.scopusqualityQ4
dc.identifier.startpage202en_US
dc.identifier.urihttps://doi.org/10.25179/tjem.2021-81148
dc.identifier.urihttps://hdl.handle.net/11491/7524
dc.identifier.volume25en_US
dc.identifier.wosWOS:000663367200010
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.institutionauthor[Belirlenecek]
dc.language.isoen
dc.publisherTurkiye Klinikleri
dc.relation.ispartofTurkish Journal Of Endocrinology And Metabolism
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectType 2 diabetesen_US
dc.subjectfirst-line therapyen_US
dc.subjectsecond-line therapyen_US
dc.subjectmetforminen_US
dc.subjectinsulinen_US
dc.subjectcomplicationsen_US
dc.subjectglycemic controlen_US
dc.subjectdyslipidemiaen_US
dc.subjectpatient-reported omesen_US
dc.titleTreatment Patterns and Associated Clinical Outcomes in Type 2 Diabetes Patients Initiating Second-Line Glucose-Lowering Therapy: Interim Analysis of Baseline Data from Turkey Arm of the Global DISCOVER Study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu